{"id":389932,"date":"2021-12-23T00:00:00","date_gmt":"2021-12-23T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0003-2021-biopharma-migraine-disease-landscape-forecast-g7-2021\/"},"modified":"2026-04-29T05:21:52","modified_gmt":"2026-04-29T05:21:52","slug":"dlsfcg0003-2021-biopharma-migraine-disease-landscape-forecast-g7-2021","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0003-2021-biopharma-migraine-disease-landscape-forecast-g7-2021\/","title":{"rendered":"Migraine | Disease Landscape &#038; Forecast | G7 | 2021"},"content":{"rendered":"<p>Migraine, which afflicts approximately 34 million people in the major pharmaceutical markets according to Clarivate epidemiology, is a heterogeneous condition requiring individualized treatment based largely on a patient\u2019s symptoms and needs, headache pattern, comorbidities, contraindications, and treatment history. With the launch of newer migraine-specific treatment alternatives (e.g., anti-CGRP MAbs for migraine prevention, gepants for the treatment of acute migraine attacks) and more on the near-term horizon, brand choice is rapidly expanding in this heavily generic market. Understanding the intersecting forces of unmet need, cost \/ coverage, and the availability of many low-cost, early-line SOCs will be key to the success of current and future players in migraine.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>What events will shape the future of the acute and preventive market segments?<\/li>\n<li>How will the anti-CGRP MAbs and gepants impact the migraine prophylaxis market? Which brands will be the most competitive and why?<\/li>\n<li>What is the dynamic between Reyvow, Ubrelvy, and Nurtec ODT? How have they been integrated into the triptan-dominant acute segment?<\/li>\n<li>How will novel reformulations compete for patient share with existing options in the niche segment of patients who need non-oral alternatives?<\/li>\n<\/ul>\n<p><strong>Product Description: <\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Solution Enhancement:<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.<\/p>\n","protected":false},"template":"","class_list":["post-389932","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-migraine","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389932","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389932\/revisions"}],"predecessor-version":[{"id":576320,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389932\/revisions\/576320"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389932"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}